On January 7, 2026, Aktis0ncol0gy, a biopharmaceutical company specializing in targeted radiopharmaceuticals, announced its expanded initial public offering of 17650.000 common shares at a price of $18.00 per share. In addition, Aktis has granted underwriters a 30 day option to purchase up to 2647500 additional ordinary shares at the initial public offering price, minus underwriting discounts and commissions.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
(4)Spray
(5)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
We provide tirzepatide powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/news/peptides-price-list-of-bloom-tech-85355837.html
The total proceeds of this issuance (before deducting underwriting discounts, commissions, and issuance fees to be paid by Aktis) are expected to be approximately $318 million, excluding the exercise of the over allotment option by the underwriters. All common stocks are provided by Aktis. Akis' common stock is expected to begin trading on NASDAQ on January 9, 2026, with the stock code "AKTS". This issuance is expected to be completed on January 12, 2026, subject to customary delivery conditions.
From the core of its business, Aktis Oncol0gy focuses on developing alpha particle radiopharmaceuticals for the treatment of common solid tumors, and its research and development pipeline has great potential. Among them, AcAKY-1189, which targets cancer expressing Nectin-4, has conducted a multicenter Phase 1b clinical trial in the United States and is currently recruiting about 150 patients. Preliminary results are expected to be announced in the first quarter of 2027;
Another Ac-AKY-2519 targeting B7-H3 tumors is planned to submit an IND application (New Drug Clinical Trial Application) in 2026, laying the foundation for further research and development.In addition, the company has established domestic and international isotope supply partnerships, invested in the construction of internal cGMP facilities (expected to be put into operation in 2026), and carried out cooperation on micro protein radioactive conjugates projects to build a comprehensive R&D and production support system.
Successful Phase I Study on the Treatment of Psoriatic Arthritis with Terpotide Combined with Yiqizhu Monoclonal Antibody
On January 8, 2026, Eli Lilly announced positive results in the Phase 1b TOGETHER PsA study of Zepbound combined with TaltzZ for the treatment of active silver shoulder arthritis (PsA) in obese or overweight subjects. This study is the first controlled clinical trial to evaluate the combination of GLP-1 drugs and PsA biologics.
Zepbound is a GIPR/GLP-IR agonist that has been approved by the FDA for the treatment of obstructive sleep apnea and obesity or overweight. Taltz (Yiqizhu monoclonal antibody) is an anti-17A monoclonal antibody that has been approved by the FDA for the treatment of active psoriatic arthritis, plaque psoriasis, active ankylosing spondylitis, and active non radiological axial spondyloarthritis.
The TOGETHER PsA study is a 52 week randomized, multicenter, evaluator blinded, open label phase 1b clinical trial (n=271) that evaluated the efficacy and safety of TalLz and Zepbound in combination with Taltz alone in adult subjects with active psoriatic arthritis complicated by obesity or overweight (BMI ≥ 30kg/m2, or BMI ≥ 27kg/m2 but<30 kg/m2) and at least one weight related complication. The main endpoint of the study was the proportion of recipients who achieved both ACR50 response and weight loss of ≥ 10% at week 36.
In terms of safety, the adverse events in the Zepbound combination therapy group were mostly mild to moderate, and the types were consistent with the known safety characteristics of each drug. Common adverse events with an incidence rate of ≥ 5% in this group include nausea, diarrhea, constipation, and injection site reactions; The common adverse events in the Taltz monotherapy group were injection site reactions and upper respiratory tract infections.
Lilly's small molecule GLP-1R agonist applied for listing in China
On January 10, 2026, the CDE website showed that Eli Lilly's small molecule GLP-1R agonist, 0rforglpron, was declared for market in China. Previously, the drug was included in the FDA approved drug list in November 2025, and Eli Lilly submitted a marketing application for the drug for weight loss to the FDA in December 2025.
Up to now, Aoqiglielon has successfully completed seven Phase I studies, including four for people with type 2 diabetes (ACHIEVE-1, ACHIEVE-2, ACHEVE-3, ACHIEVE-5), two for obese or overweight people (ATTACIN-1, ATTACIN-MAINTAIN), and one for obese or overweight people with type 2 diabetes (ATTACIN-2). Relevant results have also been disclosed.
0rforglipron is a daily oral small molecule GLP-1 receptor agonist discovered by Chinese and foreign pharmaceutical companies and developed globally by Lilly, which is used to treat type 2 diabetes and obesity. As the world's closest oral small molecule GLP-1 drug to market, 0rforglipron has successfully completed phase I clinical trials and officially submitted a marketing application to the FDA on December 18, 2024.
According to the top line data of the ACHIEVE-3 study released by Lilly in September 2025, in the head to head test for patients with type 2 diabetes, 0rforglipron's efficacy in reducing blood sugar and weight is significantly better than Novo Nordisk's oral smeglutide. The weight management data is particularly impressive: the 36mg dose group lost an average of 8.9kg (weight loss rate 9.2%), far exceeding the 5.0kg (weight loss rate 5.3%) of the oral semaglutide 14mg group, with a relative advantage of 73.6%; The average weight loss of the 12mg dose group was 6.6kg (weight loss rate 6.7%), which was also better than the 3.6kg (weight loss rate 3.7%) of the oral semaglutide 7mg group